ASLAN Pharmaceuticals Limited (ASLN)
- Previous Close
0.4060 - Open
0.4000 - Bid 0.4120 x 100
- Ask 0.4175 x 100
- Day's Range
0.3939 - 0.4200 - 52 Week Range
0.3920 - 4.4820 - Volume
167,250 - Avg. Volume
1,270,103 - Market Cap (intraday)
9.051M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-2.7500 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.50
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
aslanpharma.comRecent News: ASLN
Performance Overview: ASLN
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASLN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASLN
Valuation Measures
Market Cap
9.19M
Enterprise Value
14.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.56
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-63.71%
Return on Equity (ttm)
--
Revenue (ttm)
12M
Net Income Avi to Common (ttm)
-44.22M
Diluted EPS (ttm)
-2.7500
Balance Sheet and Cash Flow
Total Cash (mrq)
21.25M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-30.01M
Research Analysis: ASLN
Company Insights: ASLN
ASLN does not have Company Insights